Knowable Magazine reports that studying dogs' cancers offers insights into human cancer, due to similar pathways and faster tumor progression, aiding quicker clinical trials.

Researchers sought to determine whether subcutaneous isatuximab would be effective for patients with newly diagnosed MM who are ineligible for transplantation.

Cancer survival has doubled in the past half a century, but around 167,000 people still die of the disease in the UK every ...

According to Research by SNS Insider, U.S. Multiple Myeloma Market is projected to reach USD 13.91 Billion by 2032, as novel drug classes, immunotherapies, and diagnostic advances reshape treatment ...

Genmab's (GMAB) stock gains as its lymphoma drug epcoritamab developed with AbbVie (ABBV) succeeds in a Phase 3 lymphoma ...

Emma Charles shares her vision for healthcare, how AI is reshaping pharma and why access to innovation must be faster and ...

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting ...

PET/CT is a critical tool for MM staging, treatment response monitoring, and the detection of extramedullary disease (EMD), the authors explained. PET/CT has also been found to be a valuable ...

Q2 2025 Earnings Conference Call August 5, 2025 10:00 AM ETCompany ParticipantsAamir Malik - Corporate ParticipantAlbert Bourla ...

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...

Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity ...